ACTRN12612001165875招募中不适用
A randomized, double-blind study to evaluate the efficacy and safety of remifentanil in subjects undergoing ceasarean section in relation to multidrug resistance protein 1 (MDR1) and mu-opioid receptor (OPRM) polymorphisms
Interni grantove agentury Ministerstva zdravotnictvi (IGA)0 个研究点目标入组 160 人开始时间: 2012年11月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •cesarean section, hypertension, preeclampsia
排除标准
- •multiparity, gestational age < 35 weeks, estimated fetal weight < 2500g, hypoxia or signs of fetal stress and mother´s hypotension
研究者
相似试验
已完成
不适用
Effect of pomegranate extract on carotid atherosclerosisAtherosclerosis, carotid artery diseaseCirculatory SystemAtherosclerosisISRCTN30768139POM Wonderful, LLC (USA)200
已完成
不适用
A study to compare the efficacy of intra-articular injection of methylprednisolone versus triamcinolone hexacetonide in patients with knee osteoarthritisMusculoskeletal DiseasesKnee osteoarthritisISRCTN15077843Hospital Heliópolis (Brazil)100
进行中（未招募）
1 期
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003402-40-PLExelixis, Inc.250
进行中（未招募）
1 期
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerEUCTR2013-003402-40-FRExelixis, Inc.188
进行中（未招募）
1 期
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancerProgressive Metastatic Medullary Thyroid CancerMedDRA version: 21.1Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003402-40-SEExelixis, Inc.250